Mumbai, Sep 28 (IANS) The market valuation of Bajaj Finance fell by Rs 4,977.99 crore this week to Rs 6,12,914.73 crore, as India’s top companies experienced sharp losses amid a bearish trend in equities.
New Delhi, Sep 28 (IANS) India emerged as one of the fastest-growing wealth markets in the world, as Indian household financial assets rose by 14.5 per cent in 2024 on a YoY basis, according to a recent report.
New Delhi, Sep 28 (IANS) India is emerging as a global leader in the hydrogen industry, with a strong focus on green hydrogen, according to a report.
New Delhi, Sep 28 (IANS) Several Indian pharmaceutical companies including Glenmark, Granules India, Sun Pharma, Zydus and Unichem are recalling medicines from the US market, according to the US Food and Drug Administration (USFDA).
Mumbai, Sep 28 (IANS) Life Insurance Corporation of India (LIC) attracted strong investor interest on the first day after the government scrapped goods and services tax (GST) on individual traditional life insurance policies.
Mumbai, Sep 28 (IANS) The coming week will be crucial for Indian equities as investors track the Reserve Bank of India’s Monetary Policy Committee (MPC) meeting, developments on the India-US trade deal, foreign institutional investor (FII) activity, and global economic cues.
New Delhi, Sep 28 (IANS) India’s commercial vehicle and passenger vehicle segments get a cautiously optimistic outlook for FY2026, with moderate growth expected in both segments amidst GST rate reductions, a report said on Sunday.
Mumbai, Sep 28 (IANS) Foreign portfolio investors (FPIs) offloaded Rs 16,422 crore worth of Indian equities last week, driven by concerns over valuations and new policy measures of US government but the sentiment is set to reverse, analysts said on Sunday.
New Delhi, Sep 28 (IANS) In a boost to the ‘Make in India’ initiative, the iPhone 17 Air and 17 models are gaining stronger traction than last year's Plus and 16 series devices in India, according to vendors and industry analysts, as the new 17 series fly off the shelves in the country.
New Delhi, Sep 28 (IANS) The 100 per cent US tariffs on branded and patented pharmaceutical drugs is not a bitter pill for the Indian drug makers, according to analysts.
